User menu

The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam

Bibliographic reference Herman, Christelle ; Vermylen, Valérie ; Norberg, Bernadette ; Wouters, Johan ; Leyssens, Tom. The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam. In: Acta Crystallographica, Section B, Vol. B69, no. --, p. 371-378 (2013)
Permanent URL http://hdl.handle.net/2078.1/132753
  1. Admiraal G., Eikelenboom J. C., Vos A., Structures of the triclinic and monoclinic modifications of (2-oxo-1-pyrrolidinyl)acetamide, 10.1107/s0567740882009431
  2. Etter M. C., MacDonald J. C., Bernstein J., Graph-set analysis of hydrogen-bond patterns in organic crystals, 10.1107/s0108768189012929
  3. Herman Christelle, Haut Benoît, Aerts Luc, Leyssens Tom, Solid–liquid phase diagrams for the determination of the solid state nature of both polymorphs of (RS)-2-(2-oxo-pyrrolidin-1-yl)-butyramide, 10.1016/j.ijpharm.2012.07.047
  4. Herman Christelle, Haut Benoît, Douieb Sélim, Larcy Aurélie, Vermylen Valérie, Leyssens Tom, Use ofin SituRaman, FBRM, and ATR-FTIR Probes for the Understanding of the Solvent-Mediated Polymorphic Transformation of II–I Etiracetam in Methanol, 10.1021/op200168g
  5. Herman Christelle, Haut Benoît, Halloin Véronique, Vermylen Valérie, Leyssens Tom, Towards the Determination of the Solubilities of the Two Enantiotropically Related Crystallographic Forms of Etiracetam in Methanol, 10.1021/op100294f
  6. Herman Christelle, Leyssens Tom, Debaste Frédéric, Haut Benoît, Detection of the II–I Etiracetam solvent-mediated polymorphic transformation through the online monitoring of the suspension apparent viscosity, 10.1016/j.jcrysgro.2011.04.009
  7. Herman Christelle, Leyssens Tom, Vermylen Valérie, Halloin Véronique, Haut Benoît, Towards an accurate and precise determination of the solid–solid transition temperature of enantiotropic systems, 10.1016/j.jct.2010.12.006
  8. Herman Christelle, Leyssens Tom, Vermylen Valérie, Halloin Véronique, Haut Benoît, A new approach for the estimation of the melting enthalpy of metastable crystalline compounds using differential scanning calorimetry : Application to the two crystallographic forms of Etiracetam, 10.1007/s10973-011-1555-0
  9. Hurtado Barbara, Koepp Matthias J., Sander Josemir W., Thompson Pamela J., The impact of levetiracetam on challenging behavior, 10.1016/j.yebeh.2006.01.003
  10. Isoherranen Nina, Yagen Boris, Soback Stefan, Roeder Michael, Schurig Volker, Bialer Meir, Pharmacokinetics of Levetiracetam and Its Enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in Dogs, 10.1046/j.1528-1157.2001.042007825.x
  11. Kenda Benoit M., Matagne Alain C., Talaga Patrice E., Pasau Patrick M., Differding Edmond, Lallemand Bénédicte I., Frycia Anne M., Moureau Florence G., Klitgaard Henrik V., Gillard Michel R., Fuks Bruno, Michel Philippe, Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity, 10.1021/jm030913e
  12. Liao Xiangmin, Gautam Mohan, Grill Andreas, Zhu Haijian Jim, Effect of position isomerism on the formation and physicochemical properties of pharmaceutical co-crystals, 10.1002/jps.21824
  13. Lyseng-Williamson, Epilepsy Drugs, 71, 489 (2011)
  14. Myerson, A. S. (2002). Handbook of Industrial Crystallization. Montvale: Butterworth-Heinemann.
  15. Picciochi Ricardo, Diogo Hermínio P., Minas da Piedade Manuel E., Thermodynamic Characterization of Three Polymorphic Forms of Piracetam, 10.1002/jps.22294
  16. Sheldrick George M., A short history ofSHELX, 10.1107/s0108767307043930
  17. Song Jian, Lou Ke-Xia, Li Xiao-Jun, Wu Xiao-Ping, Feng Rong-Xiu, 2-(2-Oxopyrrolidin-1-yl)butyramide, 10.1107/s1600536803022578
  18. Springuel Géraldine, Leyssens Tom, Innovative Chiral Resolution Using Enantiospecific Co-Crystallization in Solution, 10.1021/cg300307z
  19. Springuel Géraldine, Norberg Bernadette, Robeyns Koen, Wouters Johan, Leyssens Tom, Advances in Pharmaceutical Co-crystal Screening: Effective Co-crystal Screening through Structural Resemblance, 10.1021/cg201291k
  20. Viertelhaus Martin, Hilfiker Rolf, Blatter Fritz, Neuburger Markus, Piracetam Co-Crystals with OH-Group Functionalized Carboxylic Acids, 10.1021/cg800942n
  21. Vishweshwar Peddy, McMahon Jennifer A., Peterson Matthew L., Hickey Magali B., Shattock Tanise R., Zaworotko Michael J., Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients, 10.1039/b501304f
  22. Oxford Diffraction (2011). CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.
  23. Altomare A., Cascarano G., Giacovazzo C., Guagliardi A., Completion and refinement of crystal structures withSIR92, 10.1107/s0021889892010331